张鹏教授团队在临床上长期从事胸部疾病的外科治疗，擅长肺癌的早期诊断及微创手术，以及局部晚期肺癌的精准治疗，科学研究专注于肺癌发生、发展、转归与肺部免疫微环境的变化等机制探索。本团队在国自然基金委杰出青年基金、优秀青年基金、重点项目、面上项目、重大研究计划培育项目等资助下，已建成肺癌相关研究的成熟平台，培养了一支素质高、竞争力强、团结互助的研究团队，团队已在Cell、Nature Genetics、Cancer cell、Immunity、Signal Transduction and Targeted Therapy、Genome Biology、Genome Medicine、BMC Medicine、Journal of Thoracic Oncology、Nucleic Acids Research、Nature Communications、Cancer Research等权威期刊发表原创性成果论文70余篇。

1. 国家自然科学基金委员会，重点项目, 82430053, 肺癌免疫治疗新靶点筛选及功能机制研究, 2025.01-2029.12, 230万元, 在研, 主持

2. 国家自然科学基金委员会，国家杰出青年科学基金, 82125001, 胸部疾病的基础和临床研究, 2022.01-2026.12, 400万元, 在研, 主持

3. 上海市教育委员会，自然科学重大项目，2023ZKZD33,非小细胞肺癌免疫治疗的新靶点与新策略，2023.01-2027.12，300万元, 在研, 主持

4. 国家自然科学基金委员会, 面上项目，81972172，LINC01094通过编码短肽调节巨噬细胞吞噬功能介导肺癌肿瘤微环境调控的机制, 2020.01-2023.12, 55万元, 在研, 结题

1. 国家自然科学基金委员会，重点项目, 82430053, 肺癌免疫治疗新靶点筛选及功能机制研究, 2025.01-2029.12, 230万元, 在研, 主持

2. 国家自然科学基金委员会，国家杰出青年科学基金, 82125001, 胸部疾病的基础和临床研究, 2022.01-2026.12, 400万元, 在研, 主持

3. 上海市教育委员会，自然科学重大项目，2023ZKZD33,非小细胞肺癌免疫治疗的新靶点与新策略，2023.01-2027.12，300万元, 在研, 主持

4. 国家自然科学基金委员会, 面上项目，81972172，LINC01094通过编码短肽调节巨噬细胞吞噬功能介导肺癌肿瘤微环境调控的机制, 2020.01-2023.12, 55万元, 在研, 结题

1. Yilv Yan#, Dongqing Sun#, JunjieHu#, Yue Chen#, Liangdong Sun, Huansha Yu, Yicheng Xiong, Zhida Huang, HaoranXia, Xinsheng Zhu, Dongliang Bian, Fenghuan Sun, Likun Hou, Chunyan Wu, OrionR. Fan, Haiyang Hu, An Zeng*,  Lele Zhang*,Yi Eve Sun*, Chenfei Wang*, Peng Zhang*. Multi-omic profilinghighlights factors associated with resistance to immuno-chemotherapy innon-small-cell lung cancer. Nature Genetics. 2025,57(1):126-139.

2. Haoran Xia#, Han Zhang#, ZhengRuan#, Huibiao Zhang#, Liangdong Sun#,  Hezhong Chen, Yongxin Zhou,  Lele Zhang, Dongliang Bian,  Xinsheng Zhu,  Jing Zhang, Fenghuan Sun, Huansha Yu, Nan Song,Xiaogang Liu, Yuming Zhu,  Haiping Zhang,Wenxin He, Jian Chen, Jie Yang, Guohan Chen, Shiliang Xie,  Dongfang Tang, Xiaomiao Zhang, Liang Duan, DepingZhao*, Qinchuan Li*,    Peng Zhang*, Gening Jiang*. Neoadjuvant camrelizumab (ananti-PD-1 antibody) plus chemotherapy or apatinib (a VEGFR-2 inhibitor) forinitially unresectable stage II-III non-small-cell lung cancer: a multicentre,two-arm, phase 2 exploratory study. SignalTransduction and Targeted Therapy. 2024, 9(1):145.

3. Qian Liu#, Jing Zhang#, ChenchenGuo#, Mengcheng Wang#, Chenfei Wang#, Yilv Yan, Liangdong Sun, Di Wang, LeleZhang, Huansha Yu, Likun Hou, Chunyan Wu, Yuming Zhu, Gening Jiang, HongwenZhu, Yanting Zhou, Shanhua Fang, Tengfei Zhang, Liang Hu, Junqiang Li, YanshengLiu, Hui Zhang, Bing Zhang, Li Ding, Ana I. Robles, Henry Rodriguez, DamingGao*, Hongbin Ji*,Hu Zhou*,Peng Zhang*. Proteogenomic characterizationof small cell lung cancer identifies biological insights and subtype-specifictherapeutic strategies, Cell. 2024,187(1): 184-203.

4.  Ningning Liu#*, Chengxiang Yi#, Luqi Wei#, Jinan Zhou, Tong Jiang, CongcongHu, Lu Wang, Yuanyuan Wang, Yun Zou, Yikai Zhao, Lele Zhang, Yating Nie,  Yijing Zhu, Xinyao Yi, Lingbing Zeng, JingquanLi, Xiaotian Huang, Hongbin Ji, Zisis Kozlakidis, Lin Zhong, ChristopherHeeschen, Xiaoqi Zheng, Changbin Chen*, Peng Zhang*, Hui Wang*. The intratumor mycobiomepromotes lung cancer progression via myeloid-derived suppressor cells, Cancer Cell. 2023, 41(11): 1927-1944.

5.  Rui Miao#, Cong Jiang#, Winston YChang#, Haiwei Zhang, Jinsu An, Felicia Ho, Pengcheng Chen, Han Zhang, CarolineJunqueira, Dulguun Amgalan, Felix G Liang, Junbing Zhang, Charles L Evavold, IvaHafner-Bratkovič, Zhibin Zhang, Pietro Fontana, Shiyu Xia, MarkusWaldeck-Weiermair, Youdong Pan, Thomas Michel, Liron Bar-Peled, Hao Wu, JonathanC Kagan, Richard N Kitsis, Peng Zhang*, Xing Liu*, Judy Lieberman*. Gasdermin D permeabilizationof mitochondrial inner and outer membranes accelerates and enhances pyroptosis. Immunity.2023, 56(11):2523-2541.

6. Dongliang Bian#, Liangdong Sun#, JunjieHu#, Liang Duan#, Haoran Xia#,  XinshengZhu, Fenghuan Sun, Lele Zhang, Huansha Yu, Yicheng Xiong,  Zhida Huang , Deping Zhao, Nan Song, Jie Yang,Xiao Bao, Wei Wu, Jie Huang, Wenxin He*, Yuming Zhu*, Gening Jiang*, Peng Zhang*.Neoadjuvant Afatinib for stage III EGFR-mutant non-small cell lung cancer: aphase II study. Nature communications.2023,14(1): 4655.

7. Junjie Hu#, Lele Zhang#, HaoranXia#, Yilv Yan#, Xinsheng Zhu, Fenghuan Sun, Liangdong Sun, Shuangyi Li, DiankeLi, Jin Wang, Ya Han, Jing Zhang, Dongliang Bian, Huansha Yu, Yan Chen, PengyuFan, Qiang Ma, Gening Jiang, Chenfei Wang*, Peng Zhang*. Tumormicroenvironment remodeling after neoadjuvant immunotherapy in non-small celllung cancer revealed by single-cell RNA sequencing. GenomeMedicine. 2023,15(1): 14.

8. Xinsheng Zhu#, Liangdong Sun#, NanSong#, Wenxin He#, Boxiong Xie#, Junjie Hu, Jing Zhang, Jie Yang, Jie Dai, DongliangBian, Haoran Xia, Fenghuan Sun, Anwen Xiong, Jie Luo, Lele Zhang, Huansha Yu, MingLiu, Hongcheng Liu, Haifeng Wang, Haiping Zhang, Chang Chen, Chunyan Wu, LiangDuan*, Yuming Zhu*, Peng Zhang*, Gening Jiang*. Safety and effectivenessof neoadjuvant PD-1 inhibitor (toripalimab) plus chemotherapy in stage II–IIINSCLC (LungMate 002): an open-label, single-arm, phase 2 trial. BMC Medicine. 2022,20(1): 493.

9. Jian Chen#, Yun Tan#, FenghuanSun#, Likun Hou, Chi Zhang, Tao Ge, Huansha Yu, Chunxiao Wu, Yuming Zhu, LiangDuan, Liang Wu, Nan Song, Liping Zhang, Wei Zhang, Di Wang, Chang Chen, ChunyanWu*, Gening Jiang*, Peng Zhang*. Single-cell transcriptome andantigen-immunoglobin analysis reveals the diversity of B cells in non-smallcell lung cancer. Genome Biology.2020, 21(1): 152

10. Jie Dai#, Ming Liu, Yang Yang, Qiuyuan Li, Nan Song,Gaetano Rocco, Alan D L Sihoe, Diego Gonzalez-Rivas, Hon Chi Suen, Wenxin He,Liang Duan, Jiang Fan, Deping Zhao, Haifeng Wang, Yuming Zhu, Chang Chen,Robert B Diasio, Gening Jiang, Ping Yang, Peng Zhang*. Optimal LymphNode Examination and Adjuvant Chemotherapy for Stage I Lung Cancer. Journal of thoracic oncology. 2019,14(7): 1277-1285